Yahoo · Oct 21, 2026
ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?
Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.
IC
NASDAQ · ICCC
ImmuCell Corporation
Healthcare · Biotechnology
$10.37
Up+$0.12 (+1.17%)
Updated Nov 5, 2026, 3:42 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 54.28M
- P/E ratio
- 23.36
- Dividend yield
- 0.00%
- 52-week range
- $6.00 – $12.10
- Volume
- 5.7K
- Avg. volume
- 18.99K
Price performance · ICCC
ICCC price history
1M range · 0 trading sessions · Daily adjusted prices
ICCC does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest ICCC news
The latest Smart Investors Daily articles mentioning ICCC.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ICCC research
Overview
Company profile and research snapshot.
Company profile
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2020 | Aegis Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 12, 2026
ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the third quarter of 2026. “Total sales for the three months ended September 30, 2026 were $8.0 million, a 46.0% increase compared to the three months ended September 30, 2025. Domestic sales were $6.
Benzinga · Oct 12, 2026
ImmuCell Sees Q3 Sales $8.000M
ImmuCell (NASDAQ:ICCC) sees Q3 sales of $8.000 million.
Benzinga · Oct 12, 2026
ImmuCell Reports Q3 Preliminary Sales Of $8M, Up 46% YoY
ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
